Parkinson’s Disease – Unmet Need – Detailed, Expanded Analysis: Psychosis In PD (US/FR/DEU/UK)
Parkinson’s disease (PD) is widely recognized as a motor disorder, but PD is also associated with a diverse set of nonmotor symptoms. Surveyed neurologists estimate that 20% of their PD patients experience psychosis, and DRG Epidemiology data suggest the percentage could be even higher. Few antipsychotic agents have been rigorously tested in the PD population, but prescribing of these agents is common; left untreated, psychosis can have a devastating effect on PD patients’ quality of life. One antipsychotic agent is approved for PD psychosis in the United States (Nuplazid) and one in Europe (clozapine), but clear unmet need remains. Understanding prescriber perceptions of the available on- and off-label options and the drivers of clinical decision-making in PD psychosis will help developers of antipsychotics and other agents gauge the market opportunity in PD and identify levers for new product positioning and differentiation in this underserved therapy market.
QUESTIONS ANSWERED
What drug attributes are most influential in prescribing for psychosis in the PD population? How do Nuplazid, clozapine, and commonly prescribed off-label agents perform on these attributes?
What are the specific areas of unmet need and opportunity in the treatment of PD psychosis?
Based on conjoint analysis and TPP simulation, what trade-offs between efficacy, safety, and price are neurologists willing to make for a hypothetical new antipsychotic agent for PD psychosis?
PRODUCT DESCRIPTION
Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 30 European neurologists, fielded in February 2020
Parkinson's Disease - Unmet Need - Detailed, Expanded Analysis: Psychosis In PD (US/FR/DEU/UK)
Executive Summary
Unmet Need - PD Psychosis - Executive Summary - March 2020
Introduction
Overview
Methodology
Rationale for Treatment Drivers and Goals Selection
Rationale for Drug Selection
Products for PD Psychosis and Rationale for Drug Selection
Treatment Drivers and Goals
Key Findings: Attribute Importance
Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Neurologists' Prescribing Decisions in PD Psychosis
Importance of Efficacy Attributes to Prescribing Decisions in PD Psychosis: United States
Importance of Efficacy Attributes to Prescribing Decisions in PD Psychosis: Europe
Importance of Safety and Tolerability Attributes to Prescribing Decisions in PD Psychosis: United States
Importance of Safety and Tolerability Attributes to Prescribing Decisions in PD Psychosis: Europe
Importance of Nonclinical Factors to Prescribing Decisions in PD Psychosis: United States
Importance of Nonclinical Factors to Prescribing Decisions in PD Psychosis: Europe
Key Findings: Stated vs. Derived Importance
Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, and Nonclinical Attributes to Prescribing Decisions in PD Psychosis: United States
Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, and Nonclinical Attributes to Prescribing Decisions in PD Psychosis: Europe
Product Performance Against Treatment Drivers and Goals
Key Findings
Overall Performance of Key Therapies for PD Psychosis: United States
Overall Performance of Key Therapies for PD Psychosis: Europe
Mean Overall Performance of Key Therapies for PD Psychosis: United States and Europe
Relative Performance of Key Therapies for PD Psychosis Across Select Efficacy Attributes: United States
Relative Performance of Key Therapies for PD Psychosis Across Select Efficacy Attributes: Europe
Relative Performance of Key Therapies for PD Psychosis Across Select Safety and Tolerability Attributes: United States
Relative Performance of Key Therapies for PD Psychosis Across Select Safety and Tolerability Attributes: Europe
Relative Performance of Key Therapies for PD Psychosis Across Select Nonclinical Attributes: United States
Relative Performance of Key Therapies for PD Psychosis Across Select Nonclinical Attributes: Europe
Assessment of Unmet Need
Key Findings: Unmet Need in PD Psychosis
Surveyed Neurologistsu2019 Satisfaction with the Performance of Key Therapies for PD Psychosis on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
Surveyed Neurologistsu2019 Satisfaction with the Performance of Key Therapies for PD Psychosis on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in PD Psychosis: United States
Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in PD Psychosis: Europe
Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in PD Psychosis: United States
Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in PD Psychosis: Europe
Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in PD Psychosis: United States
Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in PD Psychosis: Europe
Key Findings: Unmet Need in PD Psychosis and Related Indications
Surveyed Neurologists' Ascribed Level of Unmet Need in PD Psychosis and Related Indications: United States
Surveyed Neurologists' Ascribed Level of Unmet Need in PD Psychosis and Related Indications: Europe
Opportunity Analysis
Areas of Opportunity in the PD Psychosis Market and Emerging Therapy Insights
Opportunity: A Novel Agent Approved for Psychosis in PD
Target Product Profiles
Assessing Drug Development Opportunities
Target Product Profile Methodology
Attributes and Attribute Levels
Attributes of Key Current Therapies for PD Psychosis
Average Improvement in SAPS-PD Score vs. Placebo: United States
Average Improvement in SAPS-PD Score vs. Placebo: Europe
Average Improvement in CGI-S Score vs. Placebo: United States
Average Improvement in CGI-S Score vs. Placebo: Europe
Average Worsening of PD Motor Function (UPDRS Part III Score) vs. Placebo: United States
Average Worsening of PD Motor Function (UPDRS Part III Score) vs. Placebo: Europe
Warning for Increased Mortality in Elderly Patients with Dementia-Related Psychosis: United States
Warning for Increased Mortality in Elderly Patients with Dementia-Related Psychosis: Europe
Incidence of Somnolence vs. Placebo: United States
Incidence of Somnolence vs. Placebo: Europe
Incidence of Dizziness and/or Postural Hypotension vs. Placebo: United States
Incidence of Dizziness and/or Postural Hypotension vs. Placebo: Europe
List Price per Day: United States
List Price per Day: Europe
Conjoint Analysis-Based Simulation of a Market Scenario
PD Psychosis Market Simulation: Share of Preference of Target Product Profiles Included in the Market Scenario
PD Psychosis Market Simulation: Likelihood to Prescribe Target Product Profiles Included in the Market Scenario
PD Psychosis Market Simulation: Target Product Profiles Included in the Market Scenario
Appendix
Key Abbreviations
Bibliography
Bethany Christmann, Ph.D.
Bethany Christmann, Ph.D., is a principal analyst on the CNS/Ophthalmology team at DRG, part of Clarivate. In this role, she covers the neurology space, specializing in Parkinson’s disease and epilepsy; she provides expert insight and authors primary market research and forecasting content focused on these and other neurology indications. Prior to joining DRG, she earned her Ph.D. in neuroscience from Brandeis University, where she studied the cellular interactions involved in memory consolidation and their link to sleep behavior.